Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
   
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  Antibodies
  Mutations
  AlzGene
  Research Models
Resources
  Jobs
  Conference Calendar
  Grants
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Expert Opinion
  Ask the Expert
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
AD Vaccine

Extending the work from the PLoS ONE study, Michael Agadjanyan proposes a new preventive vaccination scheme for Alzheimer disease. This multivalent DNA epitope vaccine would contain currently known T helper (Th) cell epitopes of various conventional vaccines (e.g., tetanus, diphtheria, pertussis, HBV, etc.) fused with three copies of the Aβ42 B cell epitope, Aβ1-11, and a strong Th2-type molecular adjuvant (e.g., MDC as reported in the PLoS ONE paper). People immunized with the conventional vaccines should develop long-lasting memory Th cells to those pathogens. Those later diagnosed with early AD or pre-AD pathology can receive the DNA vaccine (e.g., mTh-Abeta1-11 fused with any potent molecular adjuvant), which should induce activation of pre-existing memory Th cells specific to the various pathogen epitopes on the multivalent vaccine and, subsequently, rapid and robust antibody production through activation of B cells specific to the Aβ component of the same vaccine. To demonstrate the feasibility of this strategy, Agadjanyan is collaborating with flu vaccine researcher Adolfo Garcia-Sastre, Mount Sinai School of Medicine, New York. They plan to use APP/Tg mice to test the potency of pre-existing memory Th cells generated in response to a conventional flu vaccine by immunizing these animals with a chimeric recombinant influenza virus expressing the immunodominant B-cell epitope of Aβ42, Aβ1-10, in the HA peptide, flu-Aβ1-10. Image credit: Michael Agadjanyan


  Submit a Comment

 
Cast your vote and/or make a comment on this page. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

 


Print this page
Email this page
Alzforum News
Text size
Share & Bookmark
Desperately

Antibodies
Collaborators
Cell Lines
Research Participants
Copyright © 1996-2008 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad